Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Abcam PLC is a biotechnology business based in the US. Abcam PLC shares (ABCM) are listed on the NASDAQ and all prices are listed in US Dollars. Abcam PLC employs 1,682 staff and has a trailing 12-month revenue of around $350.4 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $14.48 |
|---|---|
| 52-week range | $12.54 - $24.00 |
| 50-day moving average | $15.05 |
| 200-day moving average | $16.68 |
| Wall St. target price | $20.81 |
| PE ratio | 209 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.07 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $14.48 from 2022-09-27
| 1 week (2022-09-21) | -7.06% |
|---|---|
| 1 month (2022-08-26) | -4.99% |
| 3 months (2022-06-28) | -0.55% |
| 6 months (2022-03-28) | -22.02% |
| 1 year (2021-09-28) | -28.81% |
|---|---|
| 2 years (2020-09-24) | N/A |
| 3 years (2019-09-24) | N/A |
| 5 years (2017-09-24) | N/A |
Valuing Abcam PLC stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abcam PLC's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Abcam PLC's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 209x. In other words, Abcam PLC shares trade at around 209x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Abcam PLC's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Abcam PLC's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $77.3 million.
The EBITDA is a measure of a Abcam PLC's overall financial performance and is widely used to measure a its profitability.
To put Abcam PLC's EBITDA into context you can compare it against that of similar companies.
| Revenue TTM | $350.4 million |
|---|---|
| Operating margin TTM | 14.61% |
| Gross profit TTM | $227.7 million |
| Return on assets TTM | 3.26% |
| Return on equity TTM | 0.69% |
| Profit margin | 2.08% |
| Book value | $3.18 |
| Market capitalisation | $3.5 billion |
TTM: trailing 12 months
We're not expecting Abcam PLC to pay a dividend over the next 12 months.
You may also wish to consider:
Abcam PLC's shares were split on a 5:1 basis on 1 December 2010. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Abcam PLC shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Abcam PLC shares which in turn could have impacted Abcam PLC's share price.
Over the last 12 months, Abcam PLC's shares have ranged in value from as little as $12.54 up to $24. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abcam PLC's is 0.6303. This would suggest that Abcam PLC's shares are less volatile than average (for this exchange).
To put Abcam PLC's beta into context you can compare it against those of similar companies.
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. .
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.
